Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The company has 47 ANDA's pending approval with the U.S.FDA
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
It is the first monoclonal antibody drug for use in any animal species
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
A toll-free helpline to be set up to help doctors and patients
The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
It will be marketed under the brand name Molunamax
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
Subscribe To Our Newsletter & Stay Updated
